REVIEW PAPER
Current perspective on smoking epidemics in Poland – statement the Polish Society of Public Health
More details
Hide details
1
Collegium Medicum, Faculty of Medicine, Cardinal Stefan Wyszyński University, Warsaw, Poland
2
Department of Population Health, Division of Public Health, Medical University, Wroclaw, Poland
3
Polish Society of Public Health, Warsaw, Poland
4
Postgraduate Medical Education Centre, Warsaw, Poland
5
National Institute of Geriatrics, Rheumatology and Rehabilitation, Gerontology, Public Health and Education Department, Warsaw, Poland
Corresponding author
Dorota Kiedik
Wroclaw Medical University
Department of Population Health
Division of Public Health, Bujwida, 50-345, Wroclaw, Poland
Ann Agric Environ Med. 2022;29(3):348-357
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Over the past years, due to better education and prevention methods, the number of daily tobacco smokers in developed countries has noticeably declined. However, the rates of tobacco addicts and number of people dying from smoke-related diseases is still alarming and smoking remains the leading cause of premature death. In Poland, despite a significant decrease in mortality, tobacco smoking is still one of the major challenges for public health care. It is expected that the number of smokers will persist on a relatively high level, resulting in a lot of needless deaths, generating high medical care costs, negatively influencing citizens’ wellbeing and harming the economy. This literature review aims at describing the current state of tobacco consumption in Poland, with emphasis on public health action for its reduction.
Review Methods:
A comprehensive literature review was conducted of extant publications and analysis of statistical data obtained from reports and scientific descriptions in the area of smoking epidemiology.
Brief description of the state of knowledge:
Despite comprehensive research confirming smoking as a high-risk factor in the development of many civilization diseases, it remains a significant issue in public health in Poland. There is an urgent need for the development of systemic measures which would help decrease tobacco use in Polish society. The study reviews the current state of tobacco use in Poland, the steps taken to reduce the number of addicted people, available harm reduction solutions and accessible methods of treatment, focusing on the source of the issue, limitations and requirements that remain to be covered in Poland. The study elaborates on national perspectives for reaching a satisfying number of smokers, ultimately leading to the complete elimination of smoking from Polish society.
REFERENCES (61)
3.
Palali A, van Ours JC. The impact of tobacco control policies on smoking initiation in eleven European countries. Eur J Health Econ. 2019 Dec 1;20(9):1287–301.
4.
Borowska A. Tendencje zmian na rynku tytoniowym w Polsce w latach 1990–2006. Zesz Nauk SGGW W Warszawie Ekon Organ Gospod Żywn. 2009;(nr 73):125–41.
5.
Biondi-Zoccai G, Sciarretta S, Bullen C, Nocella C, Violi F, Loffredo L, et al. Acute Effects of Heat-Not-Burn, Electronic Vaping, and Traditional Tobacco Combustion Cigarettes: The Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking (SUR – VAPES) 2 Randomized Trial. J Am Heart Assoc. 2019 Mar 19;8(6):e010455.
9.
King C, Mulugeta A, Nabi F, Walton R, Zhou A, Hyppönen E. Mendelian randomization case-control PheWAS in UK Biobank shows evidence of causality for smoking intensity in 28 distinct clinical conditions. EClinicalMedicine [Internet]. 2020 Sep 1 [cited 2021 Dec 3];26. Available from:
https://www.thelancet.com/jour....
13.
Hosseinpoor AR, Parker LA, Tursan d’Espaignet E, Chatterji S. Socioeconomic Inequality in Smoking in Low-Income and Middle-Income Countries: Results from the World Health Survey. PLoS ONE. 2012 Aug 29;7(8):e42843.
14.
Sreeramareddy CT, Harper S, Ernstsen L. Educational and wealth inequalities in tobacco use among men and women in 54 low-income and middle-income countries. Tob Control. 2018 Jan 1;27(1):26–34.
15.
Przewozniak K, Lobaszewski J, Manczuk M, Didkowska J. Research activities in the field of tobacco control in Poland. Tob Prev Cessat [Internet]. 2018 Jun 13 [cited 2021 Dec 3];4(Supplement). Available from:
http://www.tobaccopreventionce....
16.
Kaleta D, Usidame B, Biliński P, Raciborski F, Samoliński B, Wojtyła A, et al. Global Adult Tobacco Survey (GATS) in Poland 2009–2010 – study strengths, limitations and lessons learned. Ann Agric Environ Med. 2012 Dec 31;19(4):717–22.
17.
Jassem J, Przewoźniak K, Zatoński W. Tobacco control in Poland—successes and challenges. Transl Lung Cancer Res. 2014 Oct;3(5):280–5.
20.
Pinkas J, Kaleta D, Zgliczyński WS, Lusawa A, Wrześniewska-Wal I, Wierzba W, et al. The Prevalence of Tobacco and E-Cigarette Use in Poland: A 2019 Nationwide Cross-Sectional Survey. Int J Environ Res Public Health. 2019 Dec;16(23):4820.
23.
West R. Tobacco smoking: Health impact, prevalence, correlates and interventions. Psychol Health. 2017 Aug 3;32(8):1018–36.
27.
Ministerie van Landbouw N en V. Possible excise increase on tobacco and alcohol in Poland – Nieuwsbericht – Agroberichten Buitenland [Internet]. Ministerie van Landbouw, Natuur en Voedselkwaliteit; 2019 [cited 2021 Dec 3]. Available from:
https://www.agroberichtenbuite....
28.
European network for smoking and tobacco prevention. 2018 Wytyczne dotyczące leczenia uzależnienia od tytoniu. European network for smoking and tobacco prevention; 2018.
29.
Motnyk M, Chrobot M, Zemła B. Chosen economic and health consequences of tobacco consumption for the state budget and the public sector. Polski Przegląd Nauk o Zdrowiu. 2016.
31.
Valkonen M, Kuusi T. Passive Smoking Induces Atherogenic Changes in Low-Density Lipoprotein. Circulation. 1998 May 26;97(20):2012–6.
32.
Jha P. The hazards of smoking and the benefits of cessation: A critical summation of the epidemiological evidence in high-income countries. Franco E, editor. eLife. 2020 Mar 24;9:e49979.
33.
OECD, Policies EO on HS and. Polska: Profil systemu ochrony zdrowia 2019. OECD Publishing; 2019. 1–24 p.
37.
Bhattacharyya D, Rai S, Neog L. Therapy for Cessation of Smoking. Med J Armed Forces India. 2008 Jul;64(3):254–9.
39.
Czart Ciecierski Ch, Cherukupalli R, Weresa M. Ekonomiczne aspekty palenia tytoniu i opodatkowania wyrobów tytoniowych w Polsce. Int Union Tuberc Lung Dis Union. 2011 Jan;5.
40.
Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2018 rok. 06/20219.
41.
NICE, National Institute for Health and Care Excellence. NICE Tobacco Harm Reduction Guidance PH45. 2020.
42.
Hoeng J, Maeder S, Vanscheeuwijck P, Peitsch MC. Assessing the lung cancer risk reduction potential of candidate modified risk tobacco products. Intern Emerg Med. 2019 Sep;14(6):821–34.
43.
Lüdicke F, Ansari SM, Lama N, Blanc N, Bosilkovska M, Donelli A, et al. Effects of Switching to a Heat-Not-Burn Tobacco Product on Biologically Relevant Biomarkers to Assess a Candidate Modified Risk Tobacco Product: A Randomized Trial. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2019 Nov;28(11):1934–43.
45.
Jawień A, Filipiak KJ, Bręborowicz A, Mrozikiewicz-Rakowska B, Szymański FM, Terlecki P, et al. Recommendations for the management of lower extremity artery disease (LEAD) based on ESVS/ /ESC 2017 guidelines. Position document of PTChN, PTNT, PTLR and SFSN PTK experts. Acta Angiol. 2019;25(4):219–69.
47.
Adriaens K, Gucht DV, Baeyens F. IQOSTM vs. e-Cigarette vs. Tobacco Cigarette: A Direct Comparison of Short-Term Effects after Overnight-Abstinence. Int J Environ Res Public Health. 2018 Dec 18;15(12):E2902.
49.
WHO. Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS). 2016.
51.
Başaran R, Güven NM, Eke BC. An Overview of iQOS® as a New Heat-Not-Burn Tobacco Product and Its Potential Effects on Human Health and the Environment. Turk J Pharm Sci. 2019 Sep;16(3):371–4.
52.
Davis B, Williams M, Talbot P. iQOS: evidence of pyrolysis and release of a toxicant from plastic. Tob Control. 2019 Jan 1;28(1):34–41.
53.
Leigh NJ, Palumbo MN, Marino AM, O’Connor RJ, Goniewicz ML. Tobacco-specific nitrosamines (TSNA) in heated tobacco product IQOS. Tob Control. 2018 Nov;27(Suppl 1):s37–8.
54.
Slob W, Soeteman-Hernández LG, Bil W, Staal YCM, Stephens WE, Talhout R. A Method for Comparing the Impact on Carcinogenicity of Tobacco Products: A Case Study on Heated Tobacco Versus Cigarettes. Risk Anal. 2020;40(7):1355–66.
55.
Ratajczak A, Jankowski P, Strus P, Feleszko W. Heat Not Burn Tobacco Product-A New Global Trend: Impact of Heat-Not-Burn Tobacco Products on Public Health, a Systematic Review. Int J Environ Res Public Health. 2020 Jan 8;17(2):E409.
56.
Kazubski B M, Durlik J, Balwicki Ł, Kaleta D. Program zwalczania następstw zdrowotnych używania wyrobów tytoniowych i wyrobów powiązanych w ramach Narodowego Programu Zdrowia [Internet]. 2019. Available from:
https://www.pzh.gov.pl/wp-cont... A P ORT-T Y T O % C 5% 8 3 -M% C 5% 81ODZ I E % C 5% B B -GRUDZIE%C5%83-2019-WERSJA-FINALNA-www.pdf, [cited 2021 Dec 3].
58.
Hagemejer J, Malinowska A, Poniatowsk G, Śmietanka A. THE SIGNIFICANCE OF THE TOBACCO PRODUCT MANUFACTURING TO POLAND’S ECONOMY. CASE – Cent Soc Econ Res. 2020:12–78.